Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs
1The Molecular Sciences Institute, Lexigen Pharmaceuticals, Berkeley, Lexington, CA 94704, MA 02173, USA. jway@lexigenpharm.com.
Abstract:
It is generally difficult to block protein-protein interactions with small-molecule drugs. A novel pharmaceutical development strategy to block protein interactions is emerging: targeted covalent modification to sterically block interactions. By this approach, compounds first interact non-covalently with a specific target protein. This interaction juxtaposes a weakly reactive group of the drug with a target amino acid sidechain, which then react by virtue of their high local concentration.
Related Concept Videos
Protein-protein Interfaces
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Protein-Protein Interfaces
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Drug-Receptor Bonds
In...
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...


